|

Becotatug Vedotin and Pucotenlimab Clinical Trials

1 actively recruiting trial

Also known as: Becotatug Vedotin(MRG003), Pucotenlimab(HX008)

Pipeline

Phase 2: 1

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1

Indications

  • Hypopharyngeal Squamous Cell Carcinoma1
  • Cancer1

Other1 trial

Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.